INNOVATION IN MEDICAL TECHNOLOGIES

IMPACT OF REGIONAL INNOVATION ECOSYSTEMS

MedTech4 Europe conference, 17 November 2020
How Europe can be more attractive for healthcare R&I

1. Bringing a diverse set of stakeholders together, combining wide sets of expertise;
2. Building on specific EU advantages of greater safety and data protection standards, as well as universal healthcare;
3. Investing in healthcare innovation through Public Private Partnerships (PPP) and large EU funding initiatives;
4. Establishing a more coordinated approach for EU regional innovation systems
**Value of regional innovation ecosystems**

• Innovation in medical technology requires the **cooperation of multiple partners** for funding, technologies development, scale up, validation and approval.

• Several innovation ecosystems mostly **supported by regional policies and local networks** (clusters, RTOs, large companies) facilitate the **interaction of partners** to speed up the R&I of innovative solutions.

• Common labs, affiliate programmes, pilot lines allowing a **common access to enabling technologies** would enable scale gains as tentatively explored with the electronic components and systems industry under the ECSEL Joint Undertaking.

• Co-investing in regional European ecosystems reinforces **trust in the EU medical technology industry locally**, including non-EU based companies.
Coordination of Regional Innovation Ecosystems

- Due to the multicultural nature of the EU, there has been an emergence of competing regional innovation ecosystems.

- Beyond individual regional ecosystems, there is a critical lack of coordination among them. A better interconnection and financial support of these innovation ecosystems throughout EU would add value to their specificities, highlighting the “hotspots” in Europe.

- A more coordinated approach would attract investment in ecosystems bringing together a wide set of expertise, stakeholders, buyers and investors to support timely access of innovative solutions and overcome obstacles that can impede the journey from R&I to patients.
Thank you

Patrick Boisseau
p.boisseau@medtecheurope.org

www.medtecheurope.org